- Home
- PTON vs BLTE Comparison
PTON vs BLTE Comparison
Compare PTON & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTON
- BLTE
- Stock Information
- Founded
- PTON 2012
- BLTE 2018
- Country
- PTON United States
- BLTE United States
- Employees
- PTON N/A
- BLTE N/A
- Industry
- PTON Recreational Games/Products/Toys
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- PTON Consumer Discretionary
- BLTE Health Care
- Exchange
- PTON Nasdaq
- BLTE Nasdaq
- Market Cap
- PTON 2.6B
- BLTE 2.1B
- IPO Year
- PTON 2019
- BLTE 2022
- Fundamental
- Price
- PTON $8.55
- BLTE $68.52
- Analyst Decision
- PTON Buy
- BLTE Strong Buy
- Analyst Count
- PTON 18
- BLTE 4
- Target Price
- PTON $8.23
- BLTE $96.67
- AVG Volume (30 Days)
- PTON 16.5M
- BLTE 45.0K
- Earning Date
- PTON 08-07-2025
- BLTE 08-11-2025
- Dividend Yield
- PTON N/A
- BLTE N/A
- EPS Growth
- PTON N/A
- BLTE N/A
- EPS
- PTON N/A
- BLTE N/A
- Revenue
- PTON $2,490,800,000.00
- BLTE N/A
- Revenue This Year
- PTON N/A
- BLTE N/A
- Revenue Next Year
- PTON $2.44
- BLTE N/A
- P/E Ratio
- PTON N/A
- BLTE N/A
- Revenue Growth
- PTON N/A
- BLTE N/A
- 52 Week Low
- PTON $2.83
- BLTE $43.70
- 52 Week High
- PTON $10.90
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- PTON 67.54
- BLTE 57.75
- Support Level
- PTON $6.84
- BLTE $68.99
- Resistance Level
- PTON $8.88
- BLTE $74.49
- Average True Range (ATR)
- PTON 0.54
- BLTE 3.38
- MACD
- PTON 0.19
- BLTE 0.25
- Stochastic Oscillator
- PTON 88.73
- BLTE 55.76
About PTON Peloton Interactive Inc.
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of bike and tread and related accessories sales, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue is generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from the International markets.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.